WordNet

the 9th letter of the Roman alphabet (同)i
a cellular structure that is postulated to exist in order to mediate between a chemical agent that acts on nervous tissue and the physiological response

PrepTutorEJDIC

『私は』私が
iodineの化学記号
=sense organ / 受信装置

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. インスリン様成長因子 Iの生理学 physiology of insulin like growth factor i
2. 成長ホルモン不感受性症候群 growth hormone insensitivity syndromes
3. ユーイング肉腫ファミリーの腫瘍の治療 treatment of the ewing sarcoma family of tumors
4. 骨肉腫のマネージメントにおける化学療法および放射線療法 chemotherapy and radiation therapy in the management of osteosarcoma
5. 小児および思春期の横紋筋肉腫および未分化型肉腫：治療 rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence treatment

English Journal

Insulin-like growth factor binding protein-4 and -5 modulate ligand-dependent estrogen receptor-α activation in breast cancer cells in an IGF-independent manner.

Hermani A, Shukla A, Medunjanin S, Werner H, Mayer D.SourceHormones and Signal Transduction Group, German Cancer Research Center, DKFZ-ZMBH Alliance, Heidelberg, Germany. Electronic address: alexander.hermani@googlemail.com.
Cellular signalling.Cell Signal.2013 Jun;25(6):1395-402. doi: 10.1016/j.cellsig.2013.02.018. Epub 2013 Mar 14.
Insulin-like growth factor binding proteins (IGFBPs) are modulators of numerous cellular processes including cell proliferation. Although IGFBPs classically act by sequestration of extracellular insulin-like growth factors (IGFs), thereby contributing to the fine-tuning of growth factor signals, IGF
PMID 23499909

Endocrine control of growth.

Murray PG, Clayton PE.AbstractHuman growth is a complex process starting at conception and completing in adolescence at the time of growth plate fusion. Growth can be divided into four phases: (1) fetal, where the predominant endocrine factors controlling growth are insulin and the insulin-like growth factors. (2) Infancy, where growth is mainly dependent upon nutrition. (3) Childhood, where the growth hormone-insulin-like growth factor-I (GH-IGF-I) axis and thyroid hormone are most important. (4) Puberty, where along with the GH-IGF-I axis the activation of the hypothalamo-pituitary-gonadal axis to generate sex steroid secretion becomes vital to the completion of growth. GH is released from the pituitary in a pulsatile fashion under the control of GHRH, Ghrelin, and somatostatin and, via a complex signal transduction cascade, initiates the release of IGF-I within many tissues but predominantly the liver and at the growth plate. IGF-I acts in an autocrine and paracrine manner via the IGF-I receptor to stimulate cell proliferation and longitudinal growth. Activation of the pituitary-gonadal axis during puberty occurs via a complex interaction of factors including kisspeptin, leptin, gonadotrophin releasing hormone, and tachykinin ultimately leading to augmentation of GH secretion, the pubertal growth spurt, and fusion of the growth plates. Many other hormones can affect the GH-IGF-I system or directly affect cell proliferation at the growth plate including thyroid hormone, vitamin D, and corticosteroids. © 2013 Wiley Periodicals, Inc.
American journal of medical genetics. Part C, Seminars in medical genetics.Am J Med Genet C Semin Med Genet.2013 May;163(2):76-85. doi: 10.1002/ajmg.c.31357.
Human growth is a complex process starting at conception and completing in adolescence at the time of growth plate fusion. Growth can be divided into four phases: (1) fetal, where the predominant endocrine factors controlling growth are insulin and the insulin-like growth factors. (2) Infancy, where
PMID 23613426

Japanese Journal

Immunolocalization of insulin-like growth factor-I (IGF-I) and its receptors (IGF-IR) in the equine epididymis

, , [他],
Journal of Reproduction and Development 61(1), 30-34, 2015
… The aim of this study was to test the hypothesis that insulin-like growth factor-I (IGF-I) and IGF-I receptor (IGF-IR) are localized in the caput, corpus, and cauda of the epididymis in an age-dependent manner. …
NAID 130004774189

Bromocriptine, a Dopamine Agonist, Increases Growth Hormone Secretion in a Patient with Acromegaly

, , , , , , , ,
The Tohoku Journal of Experimental Medicine 234(2), 129-135, 2014
… Serum GH and insulin-like growth factor-I (IGF-I) levels were elevated in several occasions (GH: 15.0-51.7 ng/mL, reference range: < … and IGF-I: 776-856 ng/mL, reference range: 57-175 ng/mL). … Histological analysis and immunohistochemistry revealed a GH-producing pituitary adenoma positive for D2-dopamine receptor. …
NAID 130004691038

Mechanism of repression of 11β-hydroxysteroid dehydrogenase type 1 by growth hormone in 3T3-L1 adipocytes

, , , ,
Endocrine Journal 61(7), 675-682, 2014
… We previously reported that GH and IGF-I decrease 11β-HSD1 activity and mRNA levels in adipocytes. … The aim of the present study was to clarify further the mechanism of repression of 11β-HSD1 activity by GH using linsitinib, an IGF-I receptor inhibitor. … The suppression of 11β-HSD1 mRNA by IGF-I was attenuated in the presence of 1 μM linsitinib (17.2% vs. 53.3% of basal level, P<0.05). …
NAID 130004443977